by Claudia Li | Mar 11, 2024 | Press Releases
Press release Florida Selects DiaCarta’s cfDNA Test (RadTox™) for Statewide Use to Detect Early Response of Cancer Treatment FollowFollow DiaCarta, a leading molecular diagnostics company specializing in personalized patient care through liquid biopsy, proudly...
by Claudia Li | Mar 4, 2024 | Press Releases
Press release DiaCarta Announces That the Oncuria® Bladder Cancer Tests Receive Medicare Coverage Effective January 1, 2024 FollowFollow DiaCarta proudly announced that the Oncuria® Bladder Cancer Tests, developed by Nonagen Bioscience and validated by DiaCarta as a...
by Claudia Li | Feb 27, 2024 | Press Releases
Press release DiaCarta, Inc. and OncoAssure Ltd. Collaborate to Launch Prostate Cancer Lab Developed Test FollowFollow DiaCarta, Inc. (“DiaCarta”), a pioneer in molecular diagnostic test development for cancer and infectious diseases, today announced that...
by Admin | Feb 20, 2024 | Press Releases
Press release DiaCarta’s RadTox™ Test to Monitor Tumor Response Receives Medicare Coverage FollowFollow DiaCarta, a leading molecular diagnostics company personalizing patient care through liquid biopsy, proudly announced that its revolutionary RadTox™ test,...
by Claudia Li | Dec 5, 2023 | Press Releases
Press release DiaCarta Launches OTC at Home Fecal Occult Blood Test to Complement its ColoScape™ Test FollowFollow DiaCarta, Ltd. (“DiaCarta”), a leading innovator in precision medicine diagnostic biomarker assays, announced today that DiaCarta received US FDA 510(k)...
by Claudia Li | Jul 24, 2023 | Press Releases
Press release DiaCarta and HMC/HML Team up for Customizing Lab Development Test Validations and Compliances in the US Market FollowFollow DiaCarta, Ltd. (“DiaCarta”), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that...
Recent Comments